{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T14:32:56Z","timestamp":1787668376524,"version":"build-2736575974"},"reference-count":67,"publisher":"Baishideng Publishing Group Inc.","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["WJCO"],"published-print":{"date-parts":[[2022,8,24]]},"DOI":"10.5306\/wjco.v13.i8.663","type":"journal-article","created":{"date-parts":[[2022,8,23]],"date-time":"2022-08-23T06:05:57Z","timestamp":1661234757000},"page":"663-674","source":"Crossref","is-referenced-by-count":7,"title":["Potential of mRNA vaccines to become versatile cancer vaccines"],"prefix":"10.5306","volume":"13","author":[{"given":"Shiu-Ying","family":"Tsao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2060","reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3390\/toxins12040241"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-022-00257-2"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-020-00190-2"},{"key":"B4","unstructured":"El-Domeiri AA. Immune response and non-specific immunotherapy in melanoma. Ann R Coll Surg Engl  1978; 60: 117-120"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.4161\/cbt.8.15.9133"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2010.03.01"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaf0685"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.27322"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.2147\/ITT.S202006"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.110393"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s12272-017-0969-z"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s11356-021-14700-0"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1601145"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019-0438"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9020148"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-021-01339-1"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9020097"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/sj.gt.3302964"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e31815ce501"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20171450"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2027906"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2034577"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2020.01.008"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1202195"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.121.056135"},{"key":"B26","doi-asserted-by":"crossref","unstructured":"Walunas TL, Lenschow DJ, Bakker CY, Linsley PS, Freeman GJ, Green JM, Thompson CB, Bluestone JA. Pillars article: CTLA-4 can function as a negative regulator of T cell activation. Immunity. 1994. 1: 405-413. J Immunol  2011; 187: 3466-3474","DOI":"10.1016\/1074-7613(94)90071-X"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.iy.12.040194.005015"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.R116.774562"},{"key":"B29","unstructured":"Conry RM, LoBuglio AF, Wright M, Sumerel L, Pike MJ, Johanning F, Benjamin R, Lu D, Curiel DT. Characterization of a messenger RNA polynucleotide vaccine vector. Cancer Res  1995; 55: 1397-1400"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1084\/jem.184.2.465"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1111\/j.0105-2896.2004.00139.x"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1080\/14653240902960411"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1097\/00000658-200204000-00013"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201343790"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2016.107"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3747\/co.26.4853"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.gendis.2018.05.003"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000337"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1172\/JCI148549"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-15-0163"},{"key":"B41","unstructured":"Tsao SY.   Metformin: An Irony of Fate? In: Tsao SY. Bridging the Gap: In This Era of Cancer Immunotherapy. Hauppauge: Nova Science, 2021: 6-57"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000981"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.2337\/dc11-1299"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3390\/biom9120846"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-17-0927"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-2994"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1615\/CritRevOncog.2018029436"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-17-2460"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.133247"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.2391"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1038\/s41551-020-00658-w"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9050486"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9020147"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2021.11.001"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2017.243"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1038\/nature23003"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines8040776"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2021.635245"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2021.101262"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-018-0327-z"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-020-02618-4"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1038\/s41578-021-00358-0"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-2424"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1186\/1748-717X-9-180"},{"key":"B65","doi-asserted-by":"crossref","unstructured":"Bauer T, Patel M, Jimeno A, Wang D, McDermott J, Zacharek S, Randolph W, Johansen L, Hopson K, Frederick J, Zaks T, Meehan RS. A Phase I, open-label, multicenter, dose escalation study of mRNA-2752, a lipid nanoparticle encapsulating mRNAs encoding human OX40L, IL-23, and IL-36\u03b3, for intratumoral injection alone and in combination with immune checkpoint blockade. In: Proceedings of the American Association for Cancer Research Annual Meeting, 2019. Cancer Res  2019; 79 (13 Suppl Abstract): Abstract CT210","DOI":"10.1158\/1538-7445.AM2019-CT210"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2016.1207842"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002614"}],"container-title":["World Journal of Clinical Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.wjgnet.com\/2218-4333\/full\/v13\/i8\/663.htm","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,23]],"date-time":"2022-08-23T06:06:08Z","timestamp":1661234768000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.wjgnet.com\/2218-4333\/full\/v13\/i8\/663.htm"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,24]]},"references-count":67,"journal-issue":{"issue":"8"},"URL":"https:\/\/doi.org\/10.5306\/wjco.v13.i8.663","relation":{},"ISSN":["2218-4333"],"issn-type":[{"value":"2218-4333","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8,24]]}}}